Home / References
  1. Bode L, The functional biology of human milk oligosaccharides, Early Hum Dev; 2015, Nov;91(11):619-22
  2. Simrén M. Manipulating the Gut Microbiome as a Treatment Strategy for Functional Gastrointestinal Disorders. Gastroenterology; 2018; Oct, 155(4):960-962.
  3. Conlon MA and Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. Nutrients. 2015; Jan; 7(1): 17–44.
  4. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut; 2001; 48: 20–7.
  5. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol; 2008; 6:765–71.
  6. Staudacher HM, Irving PM, Lomer MC, et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol; 2014; 11:256-266.
  7. National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management. Clinical Guideline [CG61]. Published: February 2008. Last updated: April 2017. Click here for text... 
  8. Lenhart A, Ferch C, Shaw M, and Chey WD. Use of Dietary Management in Irritable Bowel Syndrome: Results of a Survey of over 1500 United States Gastroenterologists. J Neurogastroenterol Motil.; 2018; Jul 30;24(3):437-451
  9. Elison, E., et al., Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr, 2016: p. 1-13.
  10. Puccio, G., et al., Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial. Journal of Pediatric Gastroenterology and Nutrition, 2017. 64(4): p. 624.
  11. Storm, HM, et al., 2′-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial, Global Pediatric Health, 2019, Volume 6: 1–10